About KCNQ2-Related Epilepsy
KCNQ2-related epilepsy encompasses a spectrum from benign familial neonatal epilepsy to severe KCNQ2 epileptic encephalopathy, caused by mutations in KCNQ2 encoding the Kv7.2 potassium channel subunit. The severe encephalopathic form (de novo mutations) presents in the first days of life with tonic seizures, EEG burst-suppression pattern, and later neurodevelopmental impairment. Ezogabine (retigabine) directly opens Kv7.2 channels; sodium channel blockers and carbamazepine are often effective.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to KCNQ2-Related Epilepsy trials.
KCNQ2 pathogenic variant class (gain-of-function versus loss-of-function) determines treatment approach and trial eligibility for targeted therapies
EEG documentation of neonatal seizures and burst-suppression pattern is required for severe encephalopathy trials
Carbamazepine or phenobarbital response in the neonatal period is important history — document efficacy and tolerability
Gene therapy and channel opener (Kv7.2 activator) trials require no prior investigational KCNQ2-targeted treatment
Patient Resources
Find recruiting KCNQ2-Related Epilepsy trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for KCNQ2-Related Epilepsy. Updated daily.